Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof
The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
1. A method for identifying a human as having an increased risk for myocardial infarction (MI), the method comprising:
a) testing nucleic acid from said human for a KIF6 polymorphism rs9471077 as represented by position 101 of SEQ ID NO:18 or its complement by contacting said nucleic acid with an oligonucleotide comprising SEQ ID NO:173;
b) detecting the presence of G at said position 101 of SEQ ID NO:18 or C at said complement; and
c) identifying said human as having an increased risk for MI due to the presence of said G or said C.
2. The method of claim 1 , wherein said method comprises preparing a sample from said human that is enriched for a nucleic acid fragment which comprises said position 101 of SEQ ID NO:18 by amplifying said nucleic acid fragment by polymerase chain reaction (PCR).
3. The method of claim 1 , wherein said detecting the presence of said G or said C comprises detecting the presence of an amplicon.
4. The method of claim 1 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
5. The method of claim 1 , wherein said human is homozygous for said G or said C.
6. The method of claim 1 , wherein said human is heterozygous for said G or said C.
7. The method of claim 1 , further comprising administering an HMG-CoA reductase inhibitor to said human.
8. A method for reducing risk of myocardial infarction (MI) in a human, the method comprising:
a) testing nucleic acid from said human for a KIF6 polymorphism rs9471077 as represented by position 101 of SEQ ID NO:18 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to G at said position 101 of SEQ ID NO:18 or C at said complement;
b) detecting the presence of said G or said C;
c) identifying said human as having an increased risk for MI due to the presence of said G or said C; and
d) administering an HMG-CoA reductase inhibitor to said human.
9. The method of claim 8 , wherein said method comprises preparing a sample from said human that is enriched for a nucleic acid fragment which comprises said position 101 of SEQ ID NO:18 by amplifying said nucleic acid fragment by polymerase chain reaction (PCR).
10. The method of claim 8 , wherein the nucleotide sequence of said oligonucleotide consists of a segment of at least 12 contiguous nucleotides of SEQ ID NO:18 or its complement that includes said position 101.
11. The method of claim 8 , wherein said oligonucleotide is an allele-specific probe.
12. The method of claim 8 , wherein said oligonucleotide is an allele-specific primer.
13. The method of claim 12 , wherein said allele-specific primer has a nucleotide sequence comprising SEQ ID NO:173.
14. The method of claim 8 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
15. The method of claim 8 , wherein said testing comprises amplifying by polymerase chain reaction (PCR) a fragment of said nucleic acid that includes said position 101 of SEQ ID NO:18 or its complement to thereby create an amplicon containing said position, and contacting said amplicon with said oligonucleotide.
16. The method of claim 8 , wherein said human is homozygous for said G or said C.
17. The method of claim 8 , wherein said human is heterozygous for said G or said C.
18. A method for reducing risk of myocardial infarction (MI) in a human, the method comprising:
a) receiving an identification of a human as having an increased risk for MI due to the presence of a KIF6 polymorphism rs9471077 comprising G at position 101 of SEQ ID NO: 22070 or C at its complement; and
b) administering an HMG-CoA reductase inhibitor to said human.
19. The method of claim 18 , wherein said human is homozygous for said G or said C.
20. The method of claim 18 , wherein said human is heterozygous for said G or said C.